PMID- 17911445
OWN - NLM
STAT- MEDLINE
DCOM- 20071212
LR  - 20220408
IS  - 0077-8923 (Print)
IS  - 0077-8923 (Linking)
VI  - 1110
DP  - 2007 Sep
TI  - Efficacy and safety of intravenous immunoglobulin in patients with metastatic 
      melanoma.
PG  - 305-14
AB  - We have previously reported studies performed both in vitro and in laboratory 
      animals, as well as a case study in humans, suggesting that intravenous 
      immunoglobulin (IVIG) may be beneficial in the treatment of malignancies, 
      including metastatic melanoma. As part of a phase II open label trial, we have 
      administered IVIG to nine patients with metastatic melanoma who had been heavily 
      treated. In two of nine (22%) patients treated every 3 weeks with IVIG (1 g/kg 
      body weight), the disease stabilized. One patient had stable disease for 8 
      months; the other for 3 months. No serious adverse events (AEs) attributable to 
      IVIG were observed. We conclude that IVIG therapy may be useful for the treatment 
      of metastatic melanoma. Furthermore, we suggest that the effects of IVIG therapy 
      might be enhanced by its use as an adjuvant in patients without evidence of 
      disease following surgery.
FAU - Schachter, Jacob
AU  - Schachter J
AD  - Institute of Oncology, Department of Medicine B, Sheba Medical Center, 
      Tel-HaShomer 52621, Ramat Gan, Israel.
FAU - Katz, Uriel
AU  - Katz U
FAU - Mahrer, Arie
AU  - Mahrer A
FAU - Barak, Dov
AU  - Barak D
FAU - David, Liat Ziegel Ben
AU  - David LZ
FAU - Nusbacher, Jacob
AU  - Nusbacher J
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/adverse effects/*immunology/*therapeutic use
MH  - Immunotherapy
MH  - Male
MH  - Melanoma/*drug therapy/*immunology/pathology
MH  - Middle Aged
MH  - Neoplasm Metastasis/immunology/pathology/therapy
MH  - Survival Rate
EDAT- 2007/10/04 09:00
MHDA- 2007/12/13 09:00
CRDT- 2007/10/04 09:00
PHST- 2007/10/04 09:00 [pubmed]
PHST- 2007/12/13 09:00 [medline]
PHST- 2007/10/04 09:00 [entrez]
AID - 1110/1/305 [pii]
AID - 10.1196/annals.1423.032 [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2007 Sep;1110:305-14. doi: 10.1196/annals.1423.032.